CEE The latest pharma news from Central and Eastern Europe (CEE), including a new report on the disparities between the region’s healthcare systems and those of Western Europe; why US companies are looking to invest in CEE; how Polish vaccine scepticism has benefited Australia; and Hungary’s manufacturing tie-up with Chinese Sinopharm.…
South Africa A roundup of the latest news from South African pharma, including Aspen’s impressive annual growth, Adcock Ingram’s full year profit drop, and Entos Pharma’s approval for Phase II clinical rials in South Africa for its COVID-19 DNA vaccine candidate. In addition, an African Union envoy says that vaccines made in…
China The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli Lilly, Merck & Co., Novartis, Novo Nordisk, and Sanofi have achieved China growth in the first half of the year despite pricing squeezes on their mature brands; and why Bayer sees huge growth potential…
Ireland The latest news from Irish pharma, including a big new R&D investment for Abbott; contact lens giant Bausch & Lomb’s EUR 90 million manufacturing investment; and a new report on the danger that confidential pricing agreements pose to sustainable medicine costs in the country. Abbott confirms new €37.8m R&D…
Spain The latest from Spanish pharma, including the Patent and Trademark Office’s warning of the importance of IP protection for medical advancements, Grifols’ expansion in Africa through a manufacturing plant in Nigeria, Almirall’s newest EMA approval, and COVID-19 vaccination updates. Spanish Patent Office: medical advances would be “inconceivable” without patents…
China The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant Simcere and German biotech Vivoryon in Alzheimer’s; Innovent’s tie-up with Ascentage; Biogen’s USD 125 million midstage MS drug pact with InnoCare; and Everest Medicines’ partnership with social media giant Tencent. Sinopharm Tops Ranking of…
USA The latest from US health care policy, including the Senate budget deal funding for a range of major health care priorities; Biden’s proposed Advanced Research Projects Agency that would reshape the government’s medical research efforts; the Senate Finance Chair’s proposal to lower prescription drug prices; the FDA’s internal investigation into…
South Africa The latest from South African pharma, including President Ramaphosa’s blunt criticism of Big Pharma, Aspen’s reception of USD 700 million in international financial aid, Adcock Ingram’s disappointing results as fewer elective surgeries and doctor visits hit their first half revenue, and the battle to bridge digital divide in COVID-19 vaccination…
Colombia The latest news from the Colombian pharma market, including a new (legal) US cannabis deal; Bayer’s updated regional strategy; a pandemic-induced OTC product boom; Faes Farma’s growth; and why prostate cancer remains a significant concern in the country. Colombia-Based Clever Leaves To Donate $25 Million Worth Of Cannabis To…
China The latest news from Chinese pharma, including a historic first approval for Fosun Kite’s CAR-T therapy Yescarta; the Big Pharma losers from the latest round of price cuts for off-patent drugs; Lonza’s new investment in Chinese API manufacturing expansion; and Dingdang Health’s recent USD 220 million financing round. Yescarta…
Brazil The latest news from Brazilian pharma, including an investigation into the country’s deal with Indian lab Bharat Biotech to purchase COVID-19 vaccines; the IP and regulatory challenges around personalised medicine in Brazil; and how domestic champion EMS surged in performance in 2020 thanks to COVID. Brazil probes Health Ministry…
Egypt As of today, the Evergreen boat that blocked global shipping when it got stuck in the Suez Canal has still not been allowed to leave Egypt. The infamous episode illustrated the complex situation that has affected global economies during the pandemic. But, for Egypt, the liberation of the canal symbolized…
See our Cookie Privacy Policy Here
